Ovarian cancer: new developments in clear cell carcinoma and hopes for targeted therapy

被引:16
|
作者
Yamashita, Yoriko [1 ]
机构
[1] Nagoya City Univ, Grad Sch Med Sci, Dept Expt Pathol & Tumor Biol, Nagoya, Aichi 4678601, Japan
基金
日本学术振兴会;
关键词
ovarian clear cell carcinoma; PI3CA mutation; ARID1A mutation; MET amplification; targeted therapy; MALIGNANT-TRANSFORMATION; HISTOLOGICAL SUBTYPES; TUMOR-SUPPRESSOR; PIK3CA GENE; ENDOMETRIOSIS; GROWTH; EXPRESSION; MUTATIONS; ARID1A; CARCINOGENESIS;
D O I
10.1093/jjco/hyu221
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Until recently, ovarian clear cell carcinoma was recognized by its unique morphology and unfavorable patient outcome primarily due to tumor chemoresistance. Recently, specific molecular characteristics of ovarian clear cell carcinoma, such as PI3CA mutation, ARID1a mutation and MET amplification, have been elucidated. In addition, an association between endometriosis and the tumor has also been a focus of research in recent years. The aim of this review is to discuss the specificity and importance of molecular changes and various intriguing points that are not solved until today. Finally, future aspects, including hopes for the development of novel therapies, are discussed.
引用
收藏
页码:405 / 407
页数:3
相关论文
共 50 条
  • [1] New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
    D S P Tan
    R E Miller
    S B Kaye
    British Journal of Cancer, 2013, 108 : 1553 - 1559
  • [2] New perspectives on molecular targeted therapy in ovarian clear cell carcinoma
    Tan, D. S. P.
    Miller, R. E.
    Kaye, S. B.
    BRITISH JOURNAL OF CANCER, 2013, 108 (08) : 1553 - 1559
  • [3] New Developments in Molecular Targeted Therapy of Ovarian Cancer
    Guan, Lu-Yao
    Lu, Yuan
    DISCOVERY MEDICINE, 2018, 26 (144) : 219 - 229
  • [4] Ovarian Clear Cell Carcinoma: Genomic Characterization, Pathogenesis and Targeted Therapy
    Xie, Yunkai
    Kong, Weimin
    Luo, Dan
    Chen, Shuning
    Zhao, Xiaoling
    Zhang, He
    ANTICANCER RESEARCH, 2023, 43 (08) : 3401 - 3410
  • [5] Evaluation of ATR Inhibitors for Targeted Therapy of Ovarian Clear Cell Carcinoma.
    Ji, Jing
    Li, Zhigui
    Sherman, Emily
    Osagie, Oloruntoba
    Mi, Shijun
    Soble, Whitney
    Li, Jessie
    Huang, Gloria
    REPRODUCTIVE SCIENCES, 2021, 28 (SUPPL 1) : 107A - 107A
  • [6] Evaluation of ATR Inhibitors for Targeted Therapy of Ovarian Clear Cell Carcinoma.
    Ji, Jing
    Li, Zhigui
    Sherman, Emily
    Osagie, Oloruntoba
    Mi, Shijun
    Huang, Gloria
    REPRODUCTIVE SCIENCES, 2020, 27 (SUPPL 1) : 118A - 118A
  • [7] Arginine deprivation as a potential targeted therapy for clear cell ovarian carcinoma.
    Xiao, Jennifer
    Ji, Ye
    Cochrane, Dawn R.
    Tessier-Cloutier, Basile
    Hoang, Lien N.
    Wang, Yikan
    Cheung, Angela
    Chow, Christine
    Colborne, Shane
    Hughes, Christopher
    Morin, Gregg B.
    Huntsman, David G.
    CLINICAL CANCER RESEARCH, 2018, 24 (15) : 29 - 29
  • [8] Osteopontin is a new target molecule for ovarian clear cell carcinoma therapy
    Matsuura, Motoki
    Suzuki, Takahiro
    Saito, Tsuyoshi
    CANCER SCIENCE, 2010, 101 (08) : 1828 - 1833
  • [9] The target therapy of ovarian clear cell carcinoma
    Jin, Ying
    Li, Yan
    Pan, Lingya
    ONCOTARGETS AND THERAPY, 2014, 7 : 1647 - 1652
  • [10] Targeted therapy - the new hopes in breast cancer treatment
    Duchnowska, Renata
    ONCOLOGY IN CLINICAL PRACTICE, 2007, 3 (03): : 128 - 134